Tadalafil Tablet
Product Images NDC 68071-3598

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc.., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3598 6)

Label for Tadalafil 5 mg tablets by NuCare Pharmaceuticals, Inc. The label states a package of 60 tablets, each containing 5 mg of tadalafil. The tablets are almond-shaped, yellow, and debossed with "049." The label includes the manufacturer as Zhejiang Huahai Pharmaceutical Co., Ltd, China, and warns to keep out of reach of children and to store at controlled temperature 68-77°F. The product is Rx only.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure of tadalafil, the active ingredient in the TADALAFIL 5 mg oral tablet by NuCare Pharmaceuticals, Inc. The diagram displays the molecular arrangement of atoms and bonds characteristic of tadalafil.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A set of four line graphs comparing blood pressure differences (tadalafil minus placebo) over time in hours. Graphs display standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressures, with data points and error bars shown over a 96-hour period.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

This image shows two line graphs depicting changes in standing and supine systolic blood pressure (mmHg) over 24 hours post-dose. It compares the effects of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo combined with doxazosin 8 mg, with both blood pressure measurements plotted against time in hours.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

Line graph depicting systolic blood pressure changes in mmHg over 12 hours following administration of tadalafil or placebo combined with doxazosin. The chart compares blood pressure at different times of tadalafil dosing (08:00 and 20:00) and corresponding placebo controls, showing fluctuations relative to baseline.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph displaying plasma tadalafil concentration (µg/L) over time (hours) for single 20-mg dose, single 5-mg dose, and once-daily 5-mg tadalafil after 5 consecutive days. The y-axis shows concentration up to 500 µg/L and the x-axis shows time up to 120 hours, with error bars indicating variability in measurements.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period comparing Tadalafil tablets 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change in score, with Tadalafil showing a greater reduction over time than placebo. Statistical significance is indicated at 12 weeks with p < 0.01.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph comparing change from baseline in IPSS total score over 12 weeks between Tadalafil tablets 5 mg and placebo. The graph shows greater score reduction with Tadalafil over time, with a statistically significant difference at week 4. The x-axis represents treatment duration in weeks, and the y-axis shows change from baseline in IPSS score.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph depicting the least squares mean change from baseline over 26 weeks of therapy. It compares Tadalafil/Finasteride versus Placebo/Finasteride at weeks 0, 4, 12, and 26. The graph includes statistical significance markers at different time points.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph depicting the change from baseline in IPSS Total Score over 12 weeks of treatment comparing tadalafil tablets 5 mg with placebo. The x-axis shows duration of treatment in weeks (0, 2, 4, 8, 12) and the y-axis indicates change in score. Tadalafil shows a greater decrease in score over time than placebo, with a statistically significant difference at week 12 (p<0.01).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.